Which Is The Better Pick For Your Portfolio: GlaxoSmithKline plc Or AstraZeneca plc?

Should you chose GlaxoSmithKline (LON: GSK) or AstraZeneca (LON: AZN) for your portfolio?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

GlaxoSmithKline (LSE: GSK) and AstraZeneca (LSE: AZN) are similar businesses, but if you could only pick one then choosing between the two is difficult.

It really comes down to your personal investment goals — are you looking for income or growth?

Income pick

Glaxo is the income play of the two pharma giants.  The company’s shares currently support a dividend yield of 5.5%, and management has made a commitment to maintaining the payout at its present level until 2017. 

Passive income stocks: our picks

Do you like the idea of dividend income?

The prospect of investing in a company just once, then sitting back and watching as it potentially pays a dividend out over and over?

If you’re excited by the thought of regular passive income payments, as well as the potential for significant growth on your initial investment…

Then we think you’ll want to see this report inside Motley Fool Share Advisor — ‘5 Essential Stocks For Passive Income Seekers’.

What’s more, today we’re giving away one of these stock picks, absolutely free!

Get your free passive income stock pick

Unfortunately, Glaxo’s management has also stated that the dividend payout won’t grow over the next three years, which is disappointing. Still, there’s scope for serious payout growth after 2017. 

Room for growth

The next three years will be a transitional period for Glaxo. The company expects 2015 core earnings per share to decline at a percentage rate “in the high teens” as sales of key drugs continue to fall.

However, new treatments will start to work their way through the company’s treatment pipeline by 2016. These new products, combined with Glaxo’s drive to cut costs by £3bn per annum by 2017, will lead to slow and steady earnings growth. 

Glaxo’s management believes that group’s revenue will grow at a low-to-mid single digit percentage per annum from 2016 to 2020. During the same period, core earnings per share are expected to expand at a rate in the mid-to-high single digits. 

City analysts believe that Glaxo’s earnings per share will fall by 11% this year before rebounding by 7% during 2016.

According to my figures, assuming a 7% per annum growth rate through to 2020, Glaxo is on track to earn 111p per share for full-year 2020. This indicates that Glaxo is trading at a 2020 P/E of 13.2. 

Exciting prospects 

Astra, on the other hand, is expecting to grow at a much faster rate than Glaxo over the next five years. 

Astra currently has 72 new cancer treatments under development, 31 of which are immuno-oncology drugs. 13 immuno-oncology drug trials are under way, with a further 16 planned at the end of November last year.

And it’s this wave of new treatments that has given Astra’s management the confidence to state that revenues will hit $45bn by 2023. 

According to my figures, which are based on Astra’s historic profit margins, on revenue of $45bn the company could report a net profit of $9bn, around £5.6bn. This translates into earnings per share of £4.43.

So, based on these figures, Astra is currently trading at a 2023 P/E of 10. 

Extra income 

Astra is set to grow rapidly over the next decade, but the company also supports a dividend yield of 4% at present. The payout is covered 1.5 times by earnings per share and isn’t expected to grow over the next few years. 

Still, a yield of 4% is above the market average of 3.4%. 

The bottom line

All in all, I’d argue that the choice is simple. If you’re looking for income, Glaxo is the better pick. However, if you’re looking for a growth play, Astra could be the best choice.

That being said, Astra does support a dividend yield of 4%, which is above the market average and complements the company’s long-term growth profile extremely well. If income investors are willing to accept a the reduced level of income, in exchange for growth potential, Astra could be the best bet. 

This AI stock is becoming a digital juggernaut in a £ 12.5 billion market!

🤖 Curious about the next big player in AI? 🤖

Our leading industry analysts have uncovered a trailblazing content platform that's revolutionising the industry with its unparalleled generative AI technology, setting new standards in creativity and efficiency.

Care for a sneak peek?

Trusted by global giants like Amazon, Disney, and Netflix, this innovative company is not just transforming digital media with AI-generated 3D content but is also capturing a significant share of a £12.7 billion market!

With a remarkable 62% gross margin, indicating exceptional profitability and operational efficiency, this company's growth trajectory positions it as a must-watch for savvy investors.

Best of all, we're offering exclusive access to the name of this game-changing stock, absolutely free!

Discover your free AI stock pick

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Rupert Hargreaves owns shares of GlaxoSmithKline. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

At $184, I reckon this S&P 500 juggernaut is still on sale

Our writer sees Amazon (NASDAQ:AMZN) as an attractive S&P 500 stock to consider while it is priced 23% lower than…

Read more »

Investing Articles

Cheap FTSE 250 shares to consider buying right now?

These FTSE 250 growth stocks had weak starts to 2025, and face short-term uncertainty. But their long-term valuations could be…

Read more »

Investing Articles

As stocks dive, is this a rare chance for ISA investors to build generational wealth?

Globally, stocks have pulled back significantly following the announcement of tariffs by the US president. Is this an opportunity for…

Read more »

Investing Articles

2 ultra-cheap shares to consider right now!

These cheap UK shares offer considerable growth and income potential over the long term, reckons our writer Royston Wild.

Read more »

Investing Articles

Legal & General Group shares go ex-dividend on 24 April – time to grab that 9% yield?

Harvey Jones holds Legal & General Group shares and is already looking forward to the next bumper dividend from this…

Read more »

Young female analyst working at her desk in the office
Investing Articles

3 FTSE 100 dividend stocks to consider buying while they’re on sale

Paul Summers reckons canny investors should think about snapping up quality, dividend-paying stocks while they're going cheap

Read more »

Investing Articles

2 cheap passive income shares to consider buying right now

The passive income we can earn from the UK stock market looks set to climb this year, and could even…

Read more »

Investing Articles

Down 15% in a month, this FTSE 100 dividend share offers investors a stunning 10.8% yield

Harvey Jones plucks out a FTSE 100 dividend share that offers frankly a quite staggering yield and is now a…

Read more »